Preclinical Data to be Presented at Keystone Symposia on Integrating Metabolism and Immunity
NEW YORK, NY, USA I June 1, 2017 I Kadmon Holdings, Inc. (NYSE:KDMN) (“Kadmon” or the “Company”) today announced preclinical data demonstrating the potential of the Company’s new glucose transporter (GLUT) inhibitors to treat autoimmune and inflammatory conditions. These are the first findings to be presented from Kadmon’s GLUT inhibitor program, which will be shared as a poster at the Keystone Symposia on Integrating Metabolism and Immunity today in Dublin, Ireland.
“Unlike normal cells, activated immune cells are highly reliant on glucose uptake for their activity,” said Masha Poyurovsky, PhD, Vice President, Head of Molecular Signaling at Kadmon and senior author of the study. “We confirmed that by cutting off this nutrient supply for immune cells, we can selectively affect pro-inflammatory activity to rebalance the overactive immune response and potentially resolve inflammation.”
Marked increase in glucose consumption is a well-characterized and requisite component of immune cell growth and activation. Kadmon researchers have developed potent, oral inhibitors of glucose transport, with the aim of blocking aberrant immune cell activity. The Company’s GLUT inhibitors have a good pharmacokinetic profile and directly block glucose uptake. Experiments in isolated human T cells demonstrated that these GLUT inhibitors blocked the secretion of pro-inflammatory cytokines, such as IL-17 and TNF-alpha, and modulated key intracellular signaling pathways in pathogenic T cells, including STAT1, STAT3 and S6K. Importantly, these GLUT inhibitors were well tolerated and reduced inflammation in mouse models at therapeutically relevant doses. These findings provide the foundation to advance Kadmon’s GLUT inhibitors toward clinical development.
“These data from Kadmon’s GLUT inhibitor program describe an important new approach to treating autoimmune and inflammatory disease,” said Lawrence K. Cohen, Ph.D., Executive Vice President, Business Development at Kadmon. “Immunometabolism represents a promising area of future research and development at Kadmon and a potential novel pharmacological intervention in autoimmune and inflammatory disease.”
About Kadmon Holdings, Inc.
Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company focused on developing innovative products for significant unmet medical needs. We have a diversified product pipeline in autoimmune and fibrotic diseases, oncology and genetic diseases.
SOURCE: Kadmon
Post Views: 28
Preclinical Data to be Presented at Keystone Symposia on Integrating Metabolism and Immunity
NEW YORK, NY, USA I June 1, 2017 I Kadmon Holdings, Inc. (NYSE:KDMN) (“Kadmon” or the “Company”) today announced preclinical data demonstrating the potential of the Company’s new glucose transporter (GLUT) inhibitors to treat autoimmune and inflammatory conditions. These are the first findings to be presented from Kadmon’s GLUT inhibitor program, which will be shared as a poster at the Keystone Symposia on Integrating Metabolism and Immunity today in Dublin, Ireland.
“Unlike normal cells, activated immune cells are highly reliant on glucose uptake for their activity,” said Masha Poyurovsky, PhD, Vice President, Head of Molecular Signaling at Kadmon and senior author of the study. “We confirmed that by cutting off this nutrient supply for immune cells, we can selectively affect pro-inflammatory activity to rebalance the overactive immune response and potentially resolve inflammation.”
Marked increase in glucose consumption is a well-characterized and requisite component of immune cell growth and activation. Kadmon researchers have developed potent, oral inhibitors of glucose transport, with the aim of blocking aberrant immune cell activity. The Company’s GLUT inhibitors have a good pharmacokinetic profile and directly block glucose uptake. Experiments in isolated human T cells demonstrated that these GLUT inhibitors blocked the secretion of pro-inflammatory cytokines, such as IL-17 and TNF-alpha, and modulated key intracellular signaling pathways in pathogenic T cells, including STAT1, STAT3 and S6K. Importantly, these GLUT inhibitors were well tolerated and reduced inflammation in mouse models at therapeutically relevant doses. These findings provide the foundation to advance Kadmon’s GLUT inhibitors toward clinical development.
“These data from Kadmon’s GLUT inhibitor program describe an important new approach to treating autoimmune and inflammatory disease,” said Lawrence K. Cohen, Ph.D., Executive Vice President, Business Development at Kadmon. “Immunometabolism represents a promising area of future research and development at Kadmon and a potential novel pharmacological intervention in autoimmune and inflammatory disease.”
About Kadmon Holdings, Inc.
Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company focused on developing innovative products for significant unmet medical needs. We have a diversified product pipeline in autoimmune and fibrotic diseases, oncology and genetic diseases.
SOURCE: Kadmon
Post Views: 28
